CSPC Pharmaceutical Group Ltd. has announced that its nintedanib esilate powder for inhalation has received clinical trial approval from the National Medical Products Administration of China. The product is intended for the treatment of idiopathic pulmonary fibrosis and also has potential applications for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF). This approval marks a significant milestone for CSPC's inhalation technology platform and supports the ongoing development of similar formulations within the company’s pipeline. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260102-11977089), on January 02, 2026, and is solely responsible for the information contained therein.